Etirinotecan pegol - JenKem Technology

Drug Profile

Etirinotecan pegol - JenKem Technology

Alternative Names: JK-1201l; PEG-irinotecan - JenKem; Pegylated irinotecan - 3SBio; Pegylated irinotecan - JenKem; SSS 22

Latest Information Update: 19 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JenKem Technology
  • Developer 3SBio; JenKem Technology
  • Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 Sep 2016 Phase-I clinical trials in Solid tumours in China (Parenteral) before September 2016 (3SBio pipeline, September 2016)
  • 09 Mar 2016 The China Food and Drug Administration approves IND application for etirinotecan pegol in Solid tumours
  • 16 Sep 2014 Etirinotecan pegol licensed to 3SBio in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top